Confidential

PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS INC. William R. Roush, Ph.D. on 09/09/2016

1	IN THE UNITED STATES DISTRICT COURT
2	FOR THE DISTRICT OF DELAWARE
3	PFIZER INC. and UCB PHARMA : GMBH : C. A. No.
4	Plaintiffs, : C. A. NO. : 1:15-cv-000079(GMS) : Consolidated
5	V. :
6	MYLAN PHARMACEUTICALS INC., :
7	Defendant. :
8	
9	
10	***RESTRICTED, CONFIDENTIAL***
11	
12	
13	Videotaped deposition of WILLIAM R. ROUSH,
14	Ph.D, taken pursuant to notice, held on Friday,
15	September 9, 2016, at the office of Kilpatrick
16	Townsend & Stockton, 1114 Avenue of the Americas,
17	New York, New York, commencing at 9:01 a.m. before
18	Jamie I. Moskowitz, RPR, CRR, a Registered
19	Professional Reporter and Notary Public.
20	* * *
21	
22	
23	
24	
25	

Confid		PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS INC. William R. Roush, Ph.D. on 09/09/2016Page	
1	BY MR. STOCKW	/ELL:	
2	Q	Any luck?	
3	A	I've looked.	
4	Q	I'll I'll move on. It's not that	
5	important of	a question.	
6	A	Okay.	
7	Q	Let me strike that and just move on.	
8	We can we	can try to find another document for	
9	you to refres	sh your recollection.	
10		Would you agree that at the time of	
11	the invention	n in 1998 that a skilled artisan would	
12	be reasonable	e in viewing 5-HMT as more hydrophilic	
13	than Tolterod	line?	
14		MS. MORAN: Objection.	
15		THE WITNESS: Would so at the time	
16	of inver	tion would a person of ordinary skill	
17	have vie	ewed 5-HMT as being more hydrophilic	
18	than Tol	terodine, that's your question?	
19	BY MR. STOCKW	IELL:	
20	Q	Yes.	
21	A	I think a person of ordinary skill at	
22	that time wou	ald have had access to the sort of	
23	log P, log D	determinations that are commonly used	
24	to assess lip	oophilicity, and would have agreed that	
25	5-HMT was pro	bably a little more hydrophilic.	

onfide	ential PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS INC. William R. Roush, Ph.D. on 09/09/2016 Page 7
1	context here is not clear. I'm sort of asking a
2	relative question here. I think we agreed that the
3	skilled artisan would view 5-HMT as more hydrophilic
4	than Tolterodine, right?
5	MS. MORAN: Objection.
6	THE WITNESS: I said and I used
7	there's a it's a little bit more hydrophilic
8	than Tolterodine.
9	BY MR. STOCKWELL:
10	Q So the question is: Would the skilled
11	artisan then view 5-HMT as potentially less
12	bioavailable than Tolterodine?
13	A And my answer repeatedly to that is,
14	no, a person of skill would not have viewed it that
15	way.
16	Q Do you at the time of the invention
17	in 1998, did skilled persons look at the
18	lipophilicity of a drug in assessing the oral
19	activity of a potential compound?
20	A Well, looking at a calculated
21	parameter and assessing are two different things.
22	Yes, a person of skill would would consider the
23	lipophilicity values from either measurement or
24	calculation. And if there were a question, if a
25	person of skill were motivated to move forward with

PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS INC. William R. Roush, Ph.D. on 09/09/2016

Page 94

	,
1	Detrol label about the pharmacodynamics of 5-HMT?
2	A I think the conclusions of the
3	the I think the label indicates that the well,
4	the label may not use the term "pharmacodynamic
5	effect," but the effect on patients of the extensive
6	metabolizers, a person of skill would appreciate
7	that for the drug generated the drug the
8	compound strike drug, the compound 5-HMT generated
9	as it was via Detrol had a pharmacodynamic effect
10	seemingly comparable to Tolterodine itself.
11	But the question in the that is
12	unanswerable in this is: What would the
13	pharmacodynamic be for on patients to whom 5-HMT
14	is directly delivered? And that is not answerable
15	by anything in the Detrol label.
16	Q Would the skilled artisan in 1998 have
17	had a high level of familiarity with Tolterodine?
18	MS. MORAN: Objection.
19	THE WITNESS: A high level of
20	familiarity. Tolterodine was part of the prior
21	art. And and the skilled artisan the
22	knowledge available about Tolterodine would
23	have been part of the knowledge available to
24	the skilled artisan.
25	But you said a high level. More so

Confid	PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS INC.entialWilliam R. Roush, Ph.D. on 09/09/2016Page 95
1	than anything else? I think not more so than
2	anything else.
3	BY MR. STOCKWELL:
4	Q Well, I mean, you've kind of focused
5	on the fact that the that the label was issued
6	only a couple of months before the priority date
7	here.
8	Wouldn't the skilled artisan as of the
9	priority date have been sort of just recently
10	looking at and investigating the label and becoming
11	familiar with Tolterodine?
12	A Just recently that given in that
13	two-month window, the person of ordinary skill would
14	have been aware of the label and would have read it
15	in comparison and context with everything else
16	that's known for other drugs used to treat OAB.
17	And and the person of skill would have made his
18	or her assessments of an appropriate starting place.
19	And, yeah, the Detrol was coming
20	onward, but it wasn't yet in widespread use. And I
21	think all of that that's why I said I put
22	Tolterodine at the cusp between my bucket two and
23	bucket one compounds, where bucket one is the area
24	from which a person of skill would select a
25	compound.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.